Adjuvant immunotherapies as a novel approach to bacterial infections

Immunotherapy

Volumn 5, Issue 4, 2013, Pages 365-381

  Helbig, Elisa T ^a   Opitz, Bastian ^a   Sander, Leif E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

adjuvant immunotherapy; bacterial infections; immune checkpoints; infectious threat; innate immunity; multidrug resistance; vita PAMPs

Indexed keywords

ALPHA HEMOLYSIN; ANA 773; BACTERIAL RNA; BETA INTERFERON; CASPASE RECRUITMENT DOMAIN PROTEIN 15; CASPASE RECRUITMENT DOMAIN PROTEIN 4; CHECKPOINT KINASE 1; CRX 524; CRX 527; CRYOPYRIN; CYTOTOXIC NECROTIZING FACTOR 1; DIAMINOPIMELIC ACID; FLAGELLIN; HEPATITIS B VACCINE; HOMEODOMAIN PROTEIN; IMIQUIMOD; INFLAMMASOME; INTERLEUKIN 18; INTERLEUKIN 1BETA CONVERTING ENZYME; MESSENGER RNA; N (3 OXODODECANOYL)HOMOSERINE LACTONE; N ACYLHOMOSERINE LACTONE; NIGERICIN; POLYINOSINIC POLYCYTIDYLIC ACID; RC 529; RESIQUIMOD; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

ACINETOBACTER INFECTION; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); ESCHERICHIA COLI; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; KLEBSIELLA PNEUMONIAE INFECTION; LISTERIA MONOCYTOGENES; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; SIGNAL TRANSDUCTION; STREPTOCOCCUS PNEUMONIAE; TISSUE INJURY; TUBERCULOSIS;

ADJUVANTS, IMMUNOLOGIC; BACTERIAL INFECTIONS; HUMANS; IMMUNE SYSTEM; IMMUNOTHERAPY;

EID: 84875966320     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.17     Document Type: Review

References (153)

1. Petersdorf RG. The doctors' dilemma. N. Engl. J. Med. 299(12), 628-634 (1978).
2. Petersdorf RG. Whither infectious diseases? Memories, manpower, and money. J. Infect. Dis. 153(2), 189-195 (1986).
3. Morens DM, Folkers GK, Fauci AS. The challenge of emerging and re-emerging infectious diseases. Nature 430(6996), 242-249 (2004).
4. Jones KE, Patel NG, Levy MA et al. Global trends in emerging infectious diseases. Nature 451(7181), 990-993 (2008).
5. Finland M. Chemotherapy of pneumonia - with special reference to the present status of sulfadiazine. N. Engl. J. Med. 225, 187-195 (1941).
6. Coates AR, Halls G, Hu Y. Novel classes of antibiotics or more of the same? Br. J. Pharmacol. 163(1), 184-194 (2011).
7. Jean SS, Hsueh PR. High burden of antimicrobial resistance in Asia. Int. J. Antimicrob. Agents 37(4), 291-295 (2011).
8. Dalton T, Cegielski P, Akksilp S et al. Prevalence of and risk factors for resistance to second-line drugs in people with multidrugresistant tuberculosis in eight countries: A prospective cohort study. Lancet 380(9851), 1406-1417 (2012).
9. Calfee DP. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci, and other Gram-positives in healthcare. Curr. Opin. Infect. Dis. 25(4), 385-394 (2012).
10. Johnson AP. Methicillin-resistant Staphylococcus aureus: The European landscape. J. Antimicrob. Chemother. 66(Suppl. 4), iv43-iv48 (2011).
11. Livermore DM. Current epidemiology and growing resistance of Gram-negative pathogens. Korean J. Intern. Med. 27(2), 128-142 (2012).
12. Peleg AY, Hooper DC. Hospital-acquired infections due to Gram-negative bacteria. N. Engl. J. Med. 362(19), 1804-1813 (2010).
13. Arias CA, Murray BE. Antibiotic-resistant bugs in the 21st century - a clinical superchallenge. N. Engl. J. Med. 360(5), 439-443 (2009).
14. Lascols C, Hackel M, Marshall SH et al. Increasing prevalence and dissemination of NDM-1 metallo-beta-lactamase in India: Data from the SMART study (2009). J. Antimicrob. Chemother. 66(9), 1992-1997 (2011).
15. Woodford N, Turton JF, Livermore DM. Multiresistant Gram-negative bacteria: The role of high-risk clones in the dissemination of antibiotic resistance. FEMS Microbiol. Rev. 35(5), 736-755 (2011).
16. Spanu T, De Angelis G, Cipriani M et al. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents Chemother. 56(8), 4516-4518 (2012).
17. Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: A systematic review and meta-analysis. J. Antimicrob. Chemother. 66(9), 1963-1971 (2011).
18. Kontopoulou K, Protonotariou E, Vasilakos K et al. Hospital outbreak caused by Klebsiella pneumoniae producing KPC-2 beta-lactamase resistant to colistin. J. Hosp. Infect. 76(1), 70-73 (2010).
19. Perry JD, Naqvi SH, Mirza IA et al. Prevalence of faecal carriage of Enterobacteriaceae with NDM-1 carbapenemase at military hospitals in Pakistan, and evaluation of two chromogenic media. J. Antimicrob. Chemother. 66(10), 2288-2294 (2011).
20. Calbo E, Freixas N, Xercavins M et al. Foodborne nosocomial outbreak of SHV1 and CTX-M-15-producing Klebsiella pneumoniae: Epidemiology and control. Clin. Infect. Dis. 52(6), 743-749 (2011).
21. Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: An environmental point prevalence study. Lancet Infect. Dis. 11(5), 355-362 (2011).
22. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin. Infect. Dis. 44(2), 159-177 (2007).
23. Heuer H, Schmitt H, Smalla K. Antibiotic resistance gene spread due to manure application on agricultural fields. Curr. Opin. Microbiol. 14(3), 236-243 (2011).
24. Forsberg KJ, Reyes A, Wang B, Selleck EM, Sommer MO, Dantas G. The shared antibiotic resistome of soil bacteria and human pathogens. Science 337(6098), 1107-1111 (2012).
25. Kak V, Sundareshan V, Modi J, Khardori NM. Immunotherapies in infectious diseases. Med. Clin. N. Am. 96(3), 455-474, ix (2012).
26. Jenner E. The three original publications on vaccination against smallpox. Harvard Classics 38(4), 1-14 (1909).
27. Detmer A, Glenting J. Live bacterial vaccines - a review and identification of potential hazards. Microb. Cell Fact. 5, 23 (2006).
28. Grange JM, Brunet LR, Rieder HL. Immune protection against tuberculosis - when is immunotherapy preferable to vaccination? Tuberculosis (Edinb.) 91(2), 179-185 (2011).
29. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54(Pt 1), 1-13 (1989).
30. Medzhitov R, Janeway CA Jr. Decoding the patterns of self and nonself by the innate immune system. Science 296(5566), 298-300 (2002).
31. Kawai T, Akira S. TLR signaling. Semin. Immunol. 19(1), 24-32 (2007).
32. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 449(7164), 819-826 (2007).
33. Martinon F, Mayor A, Tschopp J. The inflammasomes: Guardians of the body. Annu. Rev. Immunol. 27, 229-265 (2009).
34. Iwasaki A, Medzhitov R. Regulation of adaptive immunity by the innate immune system. Science 327(5963), 291-295 (2010).
35. Eisenbarth SC, Colegio OR, O'Connor W, Sutterwala FS, Flavell RA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 453(7198), 1122-1126 (2008).
36. Seubert A, Calabro S, Santini L et al. Adjuvanticity of the oil-in-water emulsion MF59 is independent of Nlrp3 inflammasome but requires the adaptor protein MyD88. Proc. Natl Acad. Sci. USA 108(27), 11169-11174 (2011).
37. Blander JM, Sander LE. Beyond pattern recognition: Five immune checkpoints for scaling the microbial threat. Nat. Rev. Immunol. 12(3), 215-225 (2012).
38. Vance RE, Isberg RR, Portnoy DA. Patterns of pathogenesis: Discrimination of pathogenic and nonpathogenic microbes by the innate immune system. Cell Host Microb. 6(1), 10-21 (2009).
39. Sander LE. Improved vaccines through targeted manipulation of the body's immunological risk-assessment? Bioessays 34(10), 876-884 (2012).
40. Sander LE, Davis MJ, Boekschoten MV et al. Detection of prokaryotic mRNA signifies microbial viability and promotes immunity. Nature 474(7351), 385-389 (2011).
41. Lauvau G, Vijh S, Kong P et al. Priming of memory but not effector CD8 T cells by a killed bacterial vaccine. Science 294(5547), 1735-1739 (2001).
42. Kawamura I, Yang J, Takaesu Y, Fujita M, Nomoto K, Mitsuyama M. Antigen provoking gamma interferon production in response to Mycobacterium bovis BCG and functional difference in T-cell responses to this antigen between viable and killed BCGimmunized mice. Infect. Immun. 62(10), 4396-4403 (1994).
43. Rathinam VA, Vanaja SK, Waggoner L et al. TRIF licenses caspase-11-dependent NLRP3 inflammasome activation by Gram-negative bacteria. Cell 150(3), 606-619 (2012).
44. Gurung P, Malireddi RK, Anand PK et al. Toll or interleukin-1 receptor (TIR) domaincontaining adaptor inducing interferon-beta (TRIF)-mediated caspase-11 protease production integrates Toll-like receptor 4 (TLR4) protein- and Nlrp3 inflammasomemediated host defense against enteropathogens. J. Biol. Chem. 287(41), 34474-34483 (2012).
45. Sotolongo J, Espana C, Echeverry A et al. Host innate recognition of an intestinal bacterial pathogen induces TRIF-dependent protective immunity. J. Exp. Med. 208(13), 2705-2716 (2011).
46. Jeyaseelan S, Young SK, Fessler MB et al. Toll/IL-1 receptor domain-containing adaptor inducing IFN-beta (TRIF)-mediated signaling contributes to innate immune responses in the lung during Escherichia coli pneumonia. J. Immunol. 178(5), 3153-3160 (2007).
47. Woodward JJ, Iavarone AT, Portnoy DA. c-di-AMP secreted by intracellular Listeria monocytogenes activates a host type I interferon response. Science 328(5986), 1703-1705 (2010).
48. Burdette DL, Monroe KM, Sotelo-Troha K et al. STING is a direct innate immune sensor of cyclic di-GMP. Nature 478(7370), 515-518 (2011).
49. Parvatiyar K, Zhang Z, Teles RM et al. The helicase DDX41 recognizes the bacterial secondary messengers cyclic di-GMP and cyclic di-AMP to activate a type I interferon immune response. Nat. Immunol. 13(12), 1155-1161 (2012).
50. Williams P, Winzer K, Chan WC, Camara M. Look who's talking: Communication and quorum sensing in the bacterial world. Philos. Trans. R. Soc. Lond. B Biol. Sci. 362(1483), 1119-1134 (2007).
51. Kravchenko VV, Kaufmann GF, Mathison JC et al. Modulation of gene expression via disruption of NF-kappaB signaling by a bacterial small molecule. Science 321(5886), 259-263 (2008).
52. Lu Q, Lin Y, Yang X et al. Regulation on expression of Toll-like receptors on monocytes after stimulation with the 3-o-C12-HSL molecule from Pseudomonas aeruginosa. Curr. Microbiol. 65(4), 384-389 (2012).
53. Wagner C, Zimmermann S, Brenner-Weiss G et al. The quorum-sensing molecule N-3- oxododecanoyl homoserine lactone (3OC12- HSL) enhances the host defence by activating human polymorphonuclear neutrophils (PMN). Anal. Bioanal. Chem. 387(2), 481-487 (2007).
54. Meixenberger K, Pache F, Eitel J et al. Listeria monocytogenes-infected human peripheral blood mononuclear cells produce IL-1beta, depending on listeriolysin O and NLRP3. J. Immunol. 184(2), 922-930 (2010).
55. Witzenrath M, Pache F, Lorenz D et al. The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J. Immunol. 187(1), 434-440 (2011).
56. Munoz-Planillo R, Franchi L, Miller LS, Nunez G. A critical role for hemolysins and bacterial lipoproteins in Staphylococcus aureusinduced activation of the Nlrp3 inflammasome. J. Immunol. 183(6), 3942-3948 (2009).
57. Kofoed EM, Vance RE. Innate immune recognition of bacterial ligands by NAIPs determines inflammasome specificity. Nature 477(7366), 592-595 (2011).
58. Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage susceptibility to anthrax lethal toxin. Nat. Genet. 38(2), 240-244 (2006).
59. Leemans JC, Cassel SL, Sutterwala FS. Sensing damage by the NLRP3 inflammasome. Immunol. Rev. 243(1), 152-162 (2011).
60. Krieg AM. CpG still rocks! Update on an accidental drug. Nucleic Acid Ther. 22(2), 77-89 (2012).
61. Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: Emerging therapeutics? Nat. Rev. Drug Discov. 9(4), 293-307 (2010).
62. Zhang X, Kraft A, Broering R, Schlaak JF, Dittmer U, Lu M. Preclinical development of TLR ligands as drugs for the treatment of chronic viral infections. Expert Opin. Drug Discov. 7(7), 597-611 (2012).
63. Goutagny N, Estornes Y, Hasan U, Lebecque S, Caux C. Targeting pattern recognition receptors in cancer immunotherapy. Target Oncol. 7(1), 29-54 (2012).
64. Hancock RE, Nijnik A, Philpott DJ. Modulating immunity as a therapy for bacterial infections. Nat. Rev. Microbiol. 10(4), 243-254 (2012).
65. Geddes K, Magalhaes JG, Girardin SE. Unleashing the therapeutic potential of NOD-like receptors. Nat. Rev. Drug Discov. 8(6), 465-479 (2009).
66. Ribes S, Adam N, Ebert S et al. The viral TLR3 agonist poly(I:C) stimulates phagocytosis and intracellular killing of Escherichia coli by microglial cells. Neurosci. Lett. 482(1), 17-20 (2010).
67. Ribes S, Ebert S, Czesnik D et al. Toll-like receptor prestimulation increases phagocytosis of Escherichia coli DH5alpha and Escherichia coli K1 strains by murine microglial cells. Infect. Immun. 77(1), 557-564 (2009).
68. Reppe K, Tschernig T, Luhrmann A et al. Immunostimulation with macrophageactivating lipopeptide-2 increased survival in murine pneumonia. Am. J. Respir. Cell Mol. Biol. 40(4), 474-481 (2009).
69. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316(5831), 1628-1632 (2007).
70. Airhart CL, Rohde HN, Bohach GA et al. Induction of innate immunity by lipid A mimetics increases survival from pneumonic plague. Microbiology 154(Pt 7), 2131-2138 (2008).
71. Cluff CW, Baldridge JR, Stover AG et al. Synthetic Toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immun. 73(5), 3044-3052 (2005).
72. Hirano T, Kodama S, Kawano T, Maeda K, Suzuki M. Monophosphoryl lipid A induced innate immune responses via TLR4 to enhance clearance of nontypeable Haemophilus influenzae and Moraxella catarrhalis from the nasopharynx in mice. FEMS Immunol. Med. Microbiol. 63(3), 407-417 (2011).
73. Munoz N, Van Maele L, Marques JM, Rial A, Sirard JC, Chabalgoity JA. Mucosal administration of flagellin protects mice from Streptococcus pneumoniae lung infection. Infect. Immun. 78(10), 4226-4233 (2010).
74. Yu FS, Cornicelli MD, Kovach MA et al. Flagellin stimulates protective lung mucosal immunity: Role of cathelicidin-related antimicrobial peptide. J. Immunol. 185(2), 1142-1149 (2010).
75. Parkinson T. The future of Toll-like receptor therapeutics. Curr. Opin. Mol. Ther. 10(1), 21-31 (2008).
76. Ruah SB, Ruah C, Van Aubel A, Abel S, Elsasser U. Efficacy of a polyvalent bacterial lysate in children with recurrent respiratory tract infections. Adv. Ther. 18(4), 151-162 (2001).
77. Steurer-Stey C, Bachmann LM, Steurer J, Tramer MR. Oral purified bacterial extracts in chronic bronchitis and COPD: Systematic review. Chest 126(5), 1645-1655 (2004).
78. Lembo A, Pelletier M, Iyer R et al. Administration of a synthetic TLR4 agonist protects mice from pneumonic tularemia. J. Immunol. 180(11), 7574-7581 (2008).
79. Arpaia N, Godec J, Lau L et al. TLR signaling is required for Salmonella typhimurium virulence. Cell 144(5), 675-688 (2011).
80. Hedayat M, Takeda K, Rezaei N. Prophylactic and therapeutic implications of Toll-like receptor ligands. Med. Res. Rev. 32(2), 294-325 (2010).
81. Arican O, Guneri F, Bilgic K, Karaoglu A. Topical imiquimod 5% cream in external anogenital warts: A randomized, double-blind, placebo-controlled study. J. Dermatol. 31(8), 627-631 (2004).
82. Lascaux AS, Caumes E, Deback C et al. Successful treatment of aciclovir and foscarnet resistant Herpes simplex virus lesions with topical imiquimod in patients infected with human immunodeficiency virus type 1. J. Med. Virol. 84(2), 194-197 (2012).
83. Pockros PJ, Guyader D, Patton H et al. Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled, doubleblind Phase IIa studies. J. Hepatol. 47(2), 174-182 (2007).
84. Bergmann JF, de Bruijne J, Hotho DM et al. Randomised clinical trial: Anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Aliment. Pharmacol. Ther. 34(4), 443-453 (2011).
85. Sousa Mda G, Reid DM, Schweighoffer E et al. Restoration of pattern recognition receptor costimulation to treat chromoblastomycosis, a chronic fungal infection of the skin. Cell Host Microbe 9(5), 436-443 (2011).
86. Sancho-Shimizu V, Perez De Diego R, Lorenzo L et al. Herpes simplex encephalitis in children with autosomal recessive and dominant TRIF deficiency. J. Clin. Invest. 121(12), 4889-4902 (2011).
87. von Bernuth H, Picard C, Jin Z et al. Pyogenic bacterial infections in humans with MyD88 deficiency. Science 321(5889), 691-696 (2008).
88. Cai S, Batra S, Shen L, Wakamatsu N, Jeyaseelan S. Both TRIF- and MyD88- dependent signaling contribute to host defense against pulmonary Klebsiella infection. J. Immunol. 183(10), 6629-6638 (2009).
89. Ye Z, Ting JP. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr. Opin. Immunol. 20(1), 3-9 (2008).
90. Fritz JH, Ferrero RL, Philpott DJ, Girardin SE. Nod-like proteins in immunity, inflammation and disease. Nat. Immunol. 7(12), 1250-1257 (2006).
91. Kufer TA, Sansonetti PJ. NLR functions beyond pathogen recognition. Nat. Immunol. 12(2), 121-128 (2011).
92. Lysenko ES, Clarke TB, Shchepetov M et al. Nod1 signaling overcomes resistance of S. pneumoniae to opsonophagocytic killing. PLoS Pathog. 3(8), e118 (2007).
93. Clement CG, Evans SE, Evans CM et al. Stimulation of lung innate immunity protects against lethal pneumococcal pneumonia in mice. Am. J. Respir. Crit. Care Med. 177(12), 1322-1330 (2008).
94. Evans SE, Scott BL, Clement CG et al. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. Am. J. Respir. Cell Mol. Biol. 42(1), 40-50 (2010).
95. Clarke TB, Davis KM, Lysenko ES, Zhou AY, Yu Y, Weiser JN. Recognition of peptidoglycan from the microbiota by Nod1 enhances systemic innate immunity. Nat. Med. 16(2), 228-231 (2010).
96. Wardowska A, Dzierzbicka K, Szarynska M et al. Analogues of muramyl dipeptide (MDP) and tuftsin limit infection and inflammation in murine model of sepsis. Vaccine 27(3), 369-374 (2009).
97. Juarez E, Carranza C, Hernandez-Sanchez F et al. NOD2 enhances the innate response of alveolar macrophages to Mycobacterium tuberculosis in humans. Eur. J. Immunol. 42(4), 880-889 (2012).
98. Divangahi M, Mostowy S, Coulombe F et al. NOD2-deficient mice have impaired resistance to Mycobacterium tuberculosis infection through defective innate and adaptive immunity. J. Immunol. 181(10), 7157-7165 (2008).
99. Field AK, Tytell AA, Lampson GP, Hilleman MR. Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes. Proc. Natl Acad. Sci. USA 58(3), 1004-1010 (1967).
100. Coffman RL, Sher A, Seder RA. Vaccine adjuvants: Putting innate immunity to work. Immunity 33(4), 492-503 (2010).
101. Walberg K, Baron S, Poast J et al. Interferon protects mice against inhalation anthrax. J. Interferon Cytokine Res. 28(10), 597-601 (2008).
102. Pyles RB, Jezek GE, Eaves-Pyles TD. Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection. Infect. Immun. 78(4), 1700-1710 (2010).
103. Lippmann J, Muller HC, Naujoks J et al. Dissection of a type I interferon pathway in controlling bacterial intracellular infection in mice. Cell. Microbiol. 13(11), 1668-1682 (2011).
104. Carrigan SO, Junkins R, Yang YJ et al. IFN regulatory factor 3 contributes to the host response during Pseudomonas aeruginosa lung infection in mice. J. Immunol. 185(6), 3602-3609 (2010).
105. Antonelli LR, Gigliotti Rothfuchs A, Goncalves R et al. Intranasal poly-IC treatment exacerbates tuberculosis in mice through the pulmonary recruitment of a pathogen-permissive monocyte/macrophage population. J. Clin. Invest. 120(5), 1674-1682 (2010).
106. Tian X, Xu F, Lung WY et al. Poly I:C enhances susceptibility to secondary pulmonary infections by Gram-positive bacteria. PLoS ONE 7(9), e41879 (2012).
107. Sancho D, Reis e Sousa C. Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu. Rev. Immunol. 30, 491-529 (2012).
108. Schoenen H, Bodendorfer B, Hitchens K et al. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol. 184(6), 2756-2760 (2010).
109. Ishikawa E, Ishikawa T, Morita YS et al. Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle. J. Exp. Med. 206(13), 2879-2888 (2009).
110. Lang R. Schoenen H.Desel C. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: Findings, implications and open questions Immunobiology 2011 26:11 1184-1191.
111. Lang R, Schoenen H, Desel C. Targeting Syk-Card9-activating C-type lectin receptors by vaccine adjuvants: Findings, implications and open questions. Immunobiology 216(11), 1184-1191 (2011). 111 Hardison SE, Brown GD. C-type lectin receptors orchestrate antifungal immunity. Nat. Immunol. 13(9), 817-822 (2012).
112. Bowie AG. Innate sensing of bacterial cyclic dinucleotides: More than just STING. Nat. Immunol. 13(12), 1137-1139 (2012).
113. Karaolis DK, Means TK, Yang D et al. Bacterial c-di-GMP is an immunostimulatory molecule. J. Immunol. 178(4), 2171-2181 (2007).
114. First demonstration of the immunostimulatory potential of bacterial second messenger molecule c-di-GMP. 114 Karaolis DK, Newstead MW, Zeng X et al. Cyclic di-GMP stimulates protective innate immunity in bacterial pneumonia. Infect. Immun. 75(10), 4942-4950 (2007).
115. Ogunniyi AD, Paton JC, Kirby AC et al. c-di-GMP is an effective immunomodulator and vaccine adjuvant against pneumococcal infection. Vaccine 26(36), 4676-4685 (2008).
116. Zhao L, Kuolee R, Harris G, Tram K, Yan H, Chen W. c-di-GMP protects against intranasal Acinetobacter baumannii infection in mice by chemokine induction and enhanced neutrophil recruitment. Int. Immunopharmacol. 11(9), 1378-1383 (2011).
117. Ebensen T, Libanova R, Schulze K, Yevsa T, Morr M, Guzman CA. Bis-(3́,5́)-cyclic dimeric adenosine monophosphate: Strong Th1/Th2/Th17 promoting mucosal adjuvant. Vaccine 29(32), 5210-5220 (2011).
118. Gray PM, Forrest G, Wisniewski T et al. Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol. 278(1-2), 113-119 (2012).
119. Madhun AS, Haaheim LR, Nostbakken JK et al. Intranasal c-di-GMP-adjuvanted plantderived H5 influenza vaccine induces multifunctional Th1 CD4+ cells and strong mucosal and systemic antibody responses in mice. Vaccine 29(31), 4973-4982 (2011).
120. Libanova R, Becker PD, Guzman CA. Cyclic di-nucleotides: New era for small molecules as adjuvants. Microb. Biotechnol. 5(2), 168-176 (2012).
121. Wu J, Sun L, Chen X et al. Cyclic GMP-AMP is an endogenous second messenger in innate immune signaling by cytosolic DNA. Science 339(6121), 826-830 (2012).
122. Sun L, Wu J, Du F, Chen X, Chen ZJ. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway. Science 339(6121), 786-791 (2012).
123. Tateda K, Ishii Y, Horikawa M et al. The Pseudomonas aeruginosa autoinducer N-3- oxododecanoyl homoserine lactone accelerates apoptosis in macrophages and neutrophils. Infect. Immun. 71(10), 5785-5793 (2003).
124. Karlsson T, Musse F, Magnusson KE, Vikstrom E. N-acylhomoserine lactones are potent neutrophil chemoattractants that act via calcium mobilization and actin remodeling. J. Leukoc. Biol. 91(1), 15-26 (2012).
125. Lee RJ, Xiong G, Kofonow JM et al. T2R38 taste receptor polymorphisms underlie susceptibility to upper respiratory infection. J. Clin. Invest. 122(11), 4145-4159 (2012).
126. Khajanchi BK, Kirtley ML, Brackman SM, Chopra AK. Immunomodulatory and protective roles of quorum-sensing signaling molecules N-acyl homoserine lactones during infection of mice with Aeromonas hydrophila. Infect. Immun. 79(7), 2646-2657 (2011).
127. Miller MB, Bassler BL. Quorum sensing in bacteria. Annu. Rev. Microbiol. 55, 165-199 (2001).
128. Kalia VC, Purohit HJ. Quenching the quorum sensing system: Potential antibacterial drug targets. Crit. Rev. Microbiol. 37(2), 121-140 (2011).
129. Hentzer M, Givskov M. Pharmacological inhibition of quorum sensing for the treatment of chronic bacterial infections. J. Clin. Invest. 112(9), 1300-1307 (2003).
130. Hentzer M, Wu H, Andersen JB et al. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J. 22(15), 3803-3815 (2003).
131. Stacy DM, Welsh MA, Rather PN, Blackwell HE. Attenuation of quorum sensing in the pathogen Acinetobacter baumannii using non-native N-acyl homoserine lactones. ACS Chem. Biol. 7(10), 1719-1728 (2012).
132. Brackman G, Cos P, Maes L, Nelis HJ, Coenye T. Quorum sensing inhibitors increase the susceptibility of bacterial biofilms to antibiotics in vitro and in vivo. Antimicrob. Agents Chemother. 55(6), 2655-2661 (2011).
133. Wu H, Song Z, Hentzer M et al. Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother. 53(6), 1054-1061 (2004).
134. Storz MP, Maurer CK, Zimmer C et al. Validation of PqsD as an anti-biofilm target in Pseudomonas aeruginosa by development of small-molecule inhibitors. J. Am. Chem. Soc. 134(39), 16143-16146 (2012).
135. Chan KG, Atkinson S, Mathee K et al. Characterization of N-acylhomoserine lactone-degrading bacteria associated with the Zingiber officinale (ginger) rhizosphere: Co-existence of quorum quenching and quorum sensing in Acinetobacter and Burkholderia. BMC Microbiol. 11, 51 (2011).
136. Stout-Delgado HW, Vaughan SE, Shirali AC, Jaramillo RJ, Harrod KS. Impaired NLRP3 inflammasome function in elderly mice during influenza infection is rescued by treatment with nigericin. J. Immunol. 188(6), 2815-2824 (2012).
137. Kupz A, Guarda G, Gebhardt T et al. NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8(+) T cells. Nat. Immunol. 13(2), 162-169 (2012).
138. Mcmahan RH, Golden-Mason L, Nishimura MI et al. Tim-3 expression on PD-1+ HCV-specific human CTLs is associated with viral persistence, and its blockade restores hepatocyte-directed in vitro cytotoxicity. J. Clin. Invest. 120(12), 4546-4557 (2010).
139. Velu V, Titanji K, Zhu B et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458(7235), 206-210 (2009).
140. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366(26), 2443-2454 (2012).
141. O'Neill LA. When signaling pathways collide: Positive and negative regulation of Toll-like receptor signal transduction. Immunity 29(1), 12-20 (2008).
142. Baetz A, Zimmermann S, Dalpke AH. Microbial immune evasion employing suppressor of cytokine signaling (SOCS) proteins. Inflamm. Allergy Drug Targets 6(3), 160-167 (2007).
143. Pauli EK, Schmolke M, Wolff T et al. Influenza A virus inhibits type I IFN signaling via NF-kappaB-dependent induction of SOCS-3 expression. PLoS Pathog. 4(11), e1000196 (2008).
144. Butowski N, Chang SM, Junck L et al. A Phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: A North American Brain Tumor Consortium (NABTC01-05). J. Neurooncol. 91(2), 175-182 (2009).
145. Romero CD, Varma TK, Hobbs JB, Reyes A, Driver B, Sherwood ER. The Toll-like receptor 4 agonist monophosphoryl lipid a augments innate host resistance to systemic bacterial infection. Infect. Immun. 79(9), 3576-3587 (2011).
146. Steinhagen F, Kinjo T, Bode C, Klinman DM. TLR-based immune adjuvants. Vaccine 29(17), 3341-3355 (2011).
147. Vijay-Kumar M, Aitken JD, Sanders CJ et al. Flagellin treatment protects against chemicals, bacteria, viruses, and radiation. J. Immunol. 180(12), 8280-8285 (2008).
148. Kinnebrew MA, Ubeda C, Zenewicz LA, Smith N, Flavell RA, Pamer EG. Bacterial flagellin stimulates Toll-like receptor 5-dependent defense against vancomycinresistant Enterococcus infection. J. Infect. Dis. 201(4), 534-543 (2010).
149. Jarchum I, Liu M, Lipuma L, Pamer EG. Toll-like receptor 5 stimulation protects mice from acute Clostridium difficile colitis. Infect. Immun. 79(4), 1498-1503 (2011).
150. Taylor DN, Treanor JJ, Sheldon EA et al. Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine 30(39), 5761-5769 (2012).
151. Talbot HK, Rock MT, Johnson C et al. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS ONE 5(12), e14442 (2010).
152. Boyer L, Magoc L, Dejardin S et al. Pathogen-derived effectors trigger protective immunity via activation of the Rac2 enzyme and the IMD or Rip kinase signaling pathway. Immunity 35(4), 536-549 (2011).
153. Brouillette E, Hyodo M, Hayakawa Y, Karaolis DK, Malouin F. 3́,5́-cyclic diguanylic acid reduces the virulence of biofilm-forming Staphylococcus aureus strains in a mouse model of mastitis infection. Antimicrob. Agents Chemother. 49(8), 3109-3113 (2005).